^
Association details:
Evidence:
Evidence Level:
Resistant: B - Late Trials
New
Title:

Analysis of A Disintegrin and Metalloprotease 17 (ADAM17) Expression as a Prognostic Marker in Ovarian Cancer Patients Undergoing First-Line Treatment Plus Bevacizumab

Published date:
08/31/2022
Excerpt:
MITO16A, a multicenter, phase IV, single-arm trial of bevacizumab in combination with carboplatin and paclitaxel was designed with the search for prognostic biomarkers as one of its primary endpoints....Tissue microarrays from 309 ovarian cancer patients enrolled in the MITO16A/MANGO-OV2 clinical trial were analyzed by immunohistochemistry for ADAM17 protein expression...a trend was observed between ADAM17 expression and residual disease on PFS, where high ADAM17 levels were predictive of worse prognosis among patients without residual disease compared to patients with residual disease at baseline….At variance with results on PFS, a significant interaction was found on OS between ADAM17 and FIGO stage, where the high expression of ADAM17 was predictive of worse prognosis among patients with FIGO stage III compared to patients with FIGO stage IV at baseline (Figure 3).
Secondary therapy:
carboplatin + paclitaxel
DOI:
https://doi.org/10.3390/diagnostics12092118